We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

One of SA’s profitable state-owned enterprises (SOE), nuclear medicine producer NTP Radioisotopes, has been reopened after a year-long shutdown that nearly brought the previously unblemished company to its knees. NTP’s products are vital for the diagnosis and treatment of various cancers, and the shortage threatened global supply. Its parent company, the Nuclear Energy Corporation of SA (Necsa), has said that it supplied almost 28% of the world’s medical isotopes used in diagnosis and treatment. Up until the safety scare, NTP had generated an annual turnover of R1.3bn. Necsa said the shutdown of its subsidiary had been caused by “minor safety issues” and “signatures not being done properly”, an explanation that was rejected by the national nuclear regulator and NTP. Necsa did not respond to questions whether its “strategic partnership” deal with Rosatom Healthcare, the healthcare division of its Russian counterpart, for the possible production of nuclear medicine being manufactured ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now